BioCryst Pharmaceuticals Inc (BCRX)vsMerck & Company Inc (MRK)
BCRX
BioCryst Pharmaceuticals Inc
$9.53
-2.16%
HEALTHCARE · Cap: $2.32B
MRK
Merck & Company Inc
$130.40
-1.11%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7325% more annual revenue ($65.77B vs $885.72M). MRK leads profitability with a 13.6% profit margin vs -51.7%. BCRX appears more attractively valued with a PEG of 9.39. MRK earns a higher WallStSmart Score of 50/100 (D+).
BCRX
Avoid31
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BCRX.
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.40
$49.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Expensive relative to growth rate
ROE of -1925.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BCRX
The strongest argument for BCRX centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BCRX
The primary concerns for BCRX are EPS Growth, PEG Ratio, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BCRX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
BCRX carries more volatility with a beta of 0.54 — expect wider price swings.
BCRX is growing revenue faster at 7.5% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioCryst Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?